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IgA nephropathy (IgAN) is a polygenic disorder and the
precise role of genetic factors remains elusive. Increasing
evidences have implicated the aberrant galactosylation of
IgA1 molecules in the pathogenesis of IgAN. The
galactosyltransferase, core 1 b3-Gal-T, and its chaperone,
Cosmc, play important roles in b1,3 glycosylation of IgA1
molecule. A case–control association study was performed to
investigate the association between single-nucleotide
polymorphisms (SNPs) of C1GALT1 and C1GALT1C1 genes and
the susceptibility to IgAN. A total of 1164 subjects were
enrolled, including 670 IgAN patients and 494 geographically
matched healthy controls. Five SNPs, 734C/T, 465A/G,
330G/T, 292C/, and 1365G/A in C1GALT1 were selected
as tagging SNPs. The D allele and DD genotype of 292C/
in IgAN patients were significantly lower than in the controls
(Po0.01). The frequency of haplotype YATIG (Y¼C or T) was
significantly lower in patients than in controls (0.0719 vs
0.1168, P¼ 2.775 104, odds ratio (OR)¼ 0.70). The
haplotype YAGDA (0.1236 vs 0.0791, P¼ 3.815 103,
OR¼ 1.77) and YATDG (0.0840 vs 0.0298, P¼ 1.258 105,
OR¼ 3.03) were significantly higher in patients than in
controls. The present study suggested that the
polymorphisms of C1GALT1 gene were associated with the
genetic susceptibility to IgAN in Chinese population.
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IgA nephropathy (IgAN), the most common primary
glomerulonephritis,1 is a complex-trait disease. The growing
evidence indicates that genetic components are involved in its
pathogenesis and variation of its clinical manifestation.
Evidence for this lies in the ethnic and geographic variations
in prevalence, familial clustering,2,3 and even linkage to a
specific locus on 6q22–23 (IGAN1).4 Most association
studies, which accounted for a large number of genetic
studies in past two decades, mainly focused on candidate
genes related to the progression of IgAN.2,5 Therefore, more
novel candidate genes based on the pathogenic mechanisms
of IgAN are needed for elucidating the topic.
In recent years, aberrant glycosylation of IgA1 molecules
has been reported6–8 in IgAN patients and considered
the most important pathogenic mechanism of the disease.9–12
It is well known that IgA1 contained a hinge region with
3–5 O-linked glycan chains. It consisted of a core 1 structure,
Galb1-3GalNAca1-R (where R is Ser/Thr), in which
the galactose may be sialylated. Sialic acid can also be
attached to N-acetylgalactosamine. It was demonstrated
in IgAN patient that the O-glycosylation pattern of
IgA1 hinge region was abnormal, with reduced content of
galactose and/or sialic acid, leading to an increase is the
exposure of internal GalNac.6–8,11 This aberrant galactosyla-
tion of serum IgA1 could favor the self-aggregation and/or
the increased binding to circulating glycoproteins, as well
as macromolecules formation with specific IgG antibodies
directed against IgA1 hinge O-glycans.11,13–15 They also could
escape the clearance by hepatic receptors for asialoglycopro-
teins.16 The evidences from other published works and our
previous studies demonstrated that IgA1 with aberrant
O-glycosylation had a higher binding capacity and stronger
biologic effects on cultured human mesangial cells, and that
could lead to accumulation and/or prolonged deposition of
IgA within the mesangium region.17,18 Therefore, we
speculated that altered hinge-region O-glycosylation of
IgA1 molecule might play a pivotal role in the pathogenesis
of IgAN.
The core 1 structure, Galb1-3GalNAca1-R, is synthe-
sized from GalNAca1-R by the action of core 1 uridine
diphosphate-galactose: Gal-NAc-a-R b1,3-galactosyltransfer-
ase (core 1 b3-Gal-T). The gene encoding the enzyme is
C1GALT1 (GeneID: 56913).19 It is mapped to chromosome
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7p14–p13, and is composed of three exons spanning 10 kb.19
Further studies revealed that the core 1 b3-Gal-T activity
required expression of a molecular chaperone designated
Cosmc (core 1 b3-Gal-T-specific molecular chaperone).20,21
Its coding gene was C1GALT1C1 (GeneID: 29071), which was
mapped to chromosome Xq24. This gene included one
encoding exon and spanned about 1 kb.20,21 Mutations of
C1GALT1C1 gene could impressively change the enzyme
activity of C1b3Gal-T.20,22 To investigate the polymorphisms
of C1GALT1 and C1GALT1C1 genes to the susceptibility of
IgAN, a case–control association study was performed on a
large Han Chinese population. Firstly, we scanned the two
genes to identify all polymorphisms within a sub-sample.
Then haplotype tagging single-nucleotide polymorphisms
(htSNPs) were selected. Secondly, the htSNPs were further
genotyped in the IgAN patients and the controls; and then
haplotype-based association analysis was used to test the
possible effect of its polymorphism on IgAN.
RESULTS
Detection of polymorphisms and linkage disequilibrium
analysis
Nine SNPs within the C1GALT1 gene were identified in 24
individuals. Seven SNPs (SNP1–SNP7) were localized to the
50 flanking region, at positions 734, 722, 552, 465,
449, 330, and 292 upstream the first transcription site,
respectively, and two SNPs (SNP8, SNP9) were localized,
respectively, in the 30 untranslation region, at positions 1365
and 1484. An insertion/deletion SNP (292C/) was
detected in the promoter region of C1GALT1 gene. Three
SNPs, 722G/T, 552A/G, 465A/G, were novel SNPs for
the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/
SNP/). Detailed information of all SNPs, along with the
minor allele frequencies, is presented in Table 1.
Pairwise linkage disequilibrium coefficients (D0) of the
nine SNPs in the C1GALT1 gene and corresponding P-values
are displayed in Table 2. The P-values were adjusted by the
number of SNPs in the gene by Bonferroni correction
(Po0.05/36¼ 0.0014). Shaded areas indicate that significant
linkage disequilibrium exists within the C1GALT1 gene. Five
polymorphic loci, SNP1 (734C/T), SNP4 (465A/G),
SNP6 (330G/T), SNP7 (292C/), and SNP8 (1365G/A),
were selected by htSNPer 1.0 software as tagging SNPs for
further investigation in the association study.
Only one SNP, T393A (rs17261572), was identified within
the exon of C1GALT1C1 gene from 46 individuals (including
12 female individuals and total 58 X chromosomes). The A
allele was identified in one patient with IgAN and one healthy
control, and the AA genotype was identified in one female
patient. Therefore, the A allele frequency of the SNP was
0.069 (4/58). Because minor allele frequency of the tagging
SNP should be more than 0.10, the T393A SNP in
C1GALT1C1 gene was not included in further analysis in
association study.
Table 1 | Polymorphisms of C1GALT1 gene were detected in 24 subjects
Marker name dbSNP name Region Positiona Allelesb Minor allele frequency
SNP1 rs9639031 50 Flankingc 734 C/T 0.250
SNP2 Novel 50 Flanking 722 G/T 0.145
SNP3 Novel 50 Flanking 552 A/G 0.043
SNP4 Novel 50 Flanking 465 A/G 0.167
SNP5 rs1008897 50 Flanking 449 A/G 0.021
SNP6 rs1008898 50 Flanking 330 G/T 0.479
SNP7 rs5882115 50 Flanking 292 C/– 0.125
SNP8 rs1047763 30 UTR 1365 G/A 0.438
SNP9 rs3807859 30 UTR 1484 T/A 0.043
aThe base immediately preceding the start of transcription numbered as 1.
bWith major allele given first and minor allele given second.
c50 Flanking means the upstream from the first transcribed nucleotide.
Table 2 | Pair-wise linkage disequilibrium coefficients in nine polymorphisms of C1GALT1 gene in 24 individuals
SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8 SNP9
SNP1 — 0.6195 0.2775 0.0535 0.2284 0.0002 1.0000 0.0000 1.0000
SNP2 0.1930 — 0.4218 0.0954 0.1073 0.3117 0.0000 0.0027 0.0192
SNP3 1.0000 1.0000 — 0.6070 0.7693 0.1988 0.4598 0.1238 0.6766
SNP4 1.0000 1.0000 0.2610 — 0.5436 0.1375 0.1250 0.0379 0.3876
SNP5 1.0000 1.0000 1.0000 1.0000 — 0.2498 0.0870 0.1948 0.0184
SNP6 1.0000 0.5000 1.0000 1.0000 1.0000 — 0.3202 0.0027 0.1010
SNP7 0.0000 1.0000 1.0000 1.0000 1.0000 0.4870 — 0.0087 0.0127
SNP8 1.0000 1.0000 1.0000 0.7140 1.0000 0.5030 1.0000 — 0.1540
SNP9 0.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 —
|D0 | below diagonal and P-value above diagonal.
Shaded numbers indicate statistical significance (Po0.0014) after adjusting for 36 multiple tests.
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Comparison of polymorphisms and haplotypes between
patients with IgAN and normal controls
Association analyses were performed separately for each SNP
and then haplotype-based analysis. Firstly, we compared the
frequency of allele and genotype between patients with IgAN
and normal controls for each SNP. The genotype and allele
distributions of the five SNPs are listed in Table 3. Single SNP
analysis indicated that the frequency of I allele in SNP7 was
significantly lower in patients with IgAN than in controls
(0.091 vs 0.129, P¼ 0.007). Moreover, SNP7 II/ID genotype
was significantly less in patients (0.179 vs 0.243, P¼ 0.004).
Neither alleles nor genotypes of other four SNPs differed
significantly between the two groups.
By the haplo.cc (implemented in the haplo.stats program)
analysis, we have calculated the different significance of
association between the susceptibility to IgAN and the
haplotypes consisted of different numbers of the five SNPs
(range from two to five SNPs). The other four SNPs except the first SNP got the largest adjusted global score statistic
(50.122) and the least global P-value (P¼ 5.950 107).
Global differences in haplotype frequency profiles between
the IgAN patients and the control group were tested by
permutation testing (20 000 permutations). We found
significant omnibus differences in haplotype frequencies
between the two groups (P¼ 0). The frequency of haplotypes
YATIG (Y¼C or T) was significantly lower in the patients
than in controls (0.0719 vs 0.1168, P¼ 2.775 104). Its
odds ratio (OR) was 0.70 (95% confidence interval:
0.51–0.97) (Table 4). The frequencies of other two haplo-
types, YAGDA (0.1236 vs 0.0791, P¼ 3.815 103) and
YATDG (0.0840 vs 0.0298, P¼ 1.258 105), were signifi-
cantly higher in patients than in controls. Their ORs were
1.77 (95% confidence interval: 1.28–2.46) and 3.03 (95%
confidence interval: 1.87–4.90), respectively (Table 4).
DISCUSSION
We performed a case–control association study to investigate
the association between the polymorphisms of C1GALT1
gene and the susceptibility to IgAN. The result revealed that
variations of C1GALT1 gene, especially haplotypes YATIG,
YAGDA, and YATDG, were associated with the susceptibility
to IgAN.
IgAN was considered to be a polygenic and multifactorial
disorder. Extensive evidences implied that the genetic
components were involved in the susceptibility and progres-
sion of IgAN.2–5,12 Linkage analysis based on familial data of
IgAN revealed that familial IgAN could be transmitted under
a dominant model with incomplete penetrance.3,4 However,
no candidate gene for IgAN was identified within these linked
intervals. Therefore, SNP analysis in the sporadic IgAN
patients would aid in identifying other genes that may be
originally implicated in this polygenic disease.
In past two decades, genetic association studies were
performed in many studies and they revealed that many
candidate genes were related to the predisposition and
progression of IgAN.2,5 Those genes included HLA (human
leukocyte antigen) gene family, T-cell receptor a or b chain
Table 3 | Allele and genotype distribution in IgAN patients
and controls
Variants Controls IgAN patients P-value
SNP1 Genotype
CC 255 332
CT 207 280
TT 32 58 0.370
Alleles
C 717 944
T 271 396 0.263
SNP4 Genotype
AA 362 499
AG 124 160
GG 8 11 0.891
Alleles
A 848 1158
G 140 182 0.685
SNP6 Genotype
TT 124 156
TG 267 338
GG 103 176 0.101
Alleles
T 515 650
G 473 690 0.084
SNP7 Genotype
DD 374 550
DI 113 118
II 7 2 0.007
Alleles
D 861 1218
I 127 122 0.004
SNP8 Genotype
AA 159 209
AG 235 326
GG 95 134 0.895
Alleles
A 553 744
G 425 594 0.653
IgAN, IgA nephropathy.
Table 4 | Haplotypes of C1GALT1 gene and the association
with IgAN
Frequency
Haplotype Control Case P-value OR (95% CI)
YATDAa 0.3521 0.3026 4.972 102 Reference
YATIG 0.1168 0.0719 2.775 104 0.70 (0.51–0.97)
YGGDA 0.1163 0.1051 3.850 101 1.08 (0.80–1.47)
YAGDG 0.2688 0.2629 7.956 101 1.12 (0.90–1.40
YAGDA 0.0791 0.1236 3.815 103 1.77 (1.28–2.46)
YATDG 0.0298 0.0840 1.258 105 3.03 (1.87–4.90)
Rareb 0.0371 0.0498 — —
#P=0
IgAN, IgA nephropathy.
aY=C or T.
bRare includes other seven types of haplotypes (individual frequencyo0.02).
#Omnibus P-value assessed empirically by permutation testing (20 000 permuta-
tions).
Bold values signifies P-values.
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genes, renin–angiotensin system-related genes, as well as
several inflammatory factor or cytokine genes. Most of these
genes were focused on the progression rather than the
pathogenesis of IgAN.2,10 On the other hand, most associa-
tion studies about IgAN have been performed within
relatively small case–control population and analyzed with a
single SNP.2,10 That might lead to that most of genetic
association studies of IgAN be lack of reproducibility. While
population-based genetic association study was performed,
the analysis in a large sample (more than 1000 individuals)
tended to produce more replicable association than in a small
one.23 Otherwise, the recent developments of htSNPs
selection and haplotype-based analysis offered more powerful
genetic association studies.
Based on the above considerations, we designed the
present genetic association study based on haplotype analysis
in a large population sample of IgAN patients and
geography-matched healthy controls. We firstly screened the
polymorphisms of C1GALT1 and C1GALT1C1 genes in a
sub-sample and detected nine SNPs and one SNP, respec-
tively. Then five htSNPs within C1GALT1 gene were selected
for further association analysis. The frequency of 292C/ D
allele or DD genotype in IgAN patients was significantly
higher than in controls. The frequency of haplotype YATIG
was significantly lower in patients than in controls, but the
frequency of haplotype YAGDA or YATDG was significantly
higher in patients than that in controls. These results suggest
that the variants of C1GALT1 gene would influence the
susceptibility of IgAN.
As we mentioned at the beginning, the core 1 b3-Gal-T
activity required expression of a molecular chaperone,
Cosmc. However, we only detected one SNP (T393A) within
the encoding region of C1GALT1C1 gene. The frequency of
its minor allele was only 0.069. It could not match the criteria
for further association analysis. On the other hand, although
the SNP, T393A (rs17261572), was reported with the amino-
acid substitution from aspartic acid to glutamic acid
(Asp131-Glu), it revealed normal core 1 b3-Gal-T activity
in a previous study.22 It suggested that the variations within
the encoding region of C1GALT1C1 gene would not be
essential for the abnormal galactosylation of IgA1.
It had been reported that the variations of C1GALT1 gene
were associated with the susceptibility to IgAN in Italian
IgAN patients (Pirulli D, Ulivi S, Zadro C, et al. Polymorph-
isms in the gene coding for the core1 B 1,3-galactosyltrans-
ferase T1 contribute to the genetic susceptibility to IgA
nephropathy. 10th International Symposium of IgA Nephro-
pathy: abstract, vol. 308, 2004). In their study, the genotype
1365G/G of C1GALT1 gene was identified, and it was
reported to associate with the susceptibility to IgAN.
Additionally, the promoter CGATW haplotype was signifi-
cantly less frequent in IgAN patients than in healthy controls.
Although the association between 1365G/A polymorphism
and susceptibility to IgAN could not be replicated in our
larger population, we found that the frequency of haplotype
YATIG was significantly lower, and the frequency of YAGDA
and YATDG was significantly higher in patients than that in
controls. Our results suggested that the 1365G/A polymorph-
ism might influence the susceptibility to IgAN in combina-
tion with other SNPs in C1GALT1 gene. In present study, we
identified seven SNPs in the promoter region of C1GALT1
gene; there were two SNPs not found in Italian population
(five SNPs). It demonstrated that it is important to screen the
polymorphisms in distinct populations, especially when from
different races. Besides the sample size, other factors such as
ethnic variation, unknown environmental factors, as well as
genetic heterogeneity of IgAN, might bring on the different
results in two populations.
How did the polymorphisms of C1GALT1 gene influence
the susceptibility to IgAN? All of five SNPs that we selected as
tagging SNPs for association analysis were located in the
regulatory region of the C1GALT1 gene. The variation might
influence the core 1 b3-Gal-T activity by regulating the
expression of C1GALT1 gene. In the previous Italian study,
they demonstrate the reduced expression of C1GALT1 in the
homozygous 1365G/G individuals, compared to those with
G/A or A/A genotypes. More studies are needed to validate
the function of identified polymorphisms.
The present genetic association study based on haplotyped
case–control analysis in a large Chinese population demon-
strated that polymorphisms of C1GALT1 gene were asso-
ciated with the susceptibility to IgA nephropathy.
MATERIALS AND METHODS
Subjects
A total of unrelated 1164 Northern Chinese were enrolled in this
study, including 670 patients with renal biopsy verified IgAN and
494 geographically matched healthy controls with normal urine
analysis and blood pressure. Diagnoses of IgAN were confirmed by
the observation of granular deposition of IgA in the glomerular
mesangium by immunofluorescence detection, as well as by the
deposition of electron dense material in mesangial ultrastructural
examination. Patients with Henoch-Schonlein purpura, systemic
lupus erythematosus, and chronic hepatic diseases were excluded by
detailed clinical and laboratory examinations. The average age of
patients at the time of renal biopsy was 31.2711.4 years (ranging
from 9 to 77 years), and the gender ratio (male to female) was
1.33:1. The glomerular filtration rate of IgAN patients was estimated
by the Modification of Diet in Renal Disease (MDRD) abbreviated
equation.24
The protocol for this genetic study was approved by the medical
ethics committee of Peking University, and informed written
consent for the genetic studies was obtained from all participants.
SNPs discovery
Genomic DNA of patients was extracted from ethylenediaminete-
traacetic acid-anticoagulated whole blood samples by the salting out
procedure.25 Reference sequences of C1GALT1 gene and
C1GALT1C1 gene were obtained from National Center for
Biotechnology Information (NCBI) Gene database (http://
www.ncbi.nlm.nih.gov/entrez). For C1GALT1 gene, genomic DNA
from 24 samples, including 12 unrelated IgAN patients and 12
unrelated healthy controls, were amplified by polymerase chain
reaction (PCR) and directly sequenced for screening of SNPs. The
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PCR amplification regions included each exon with 50–100 bp of
flanking intronic sequence, 50 and 30 untranslated regions, as well as
the 1 kb upstream from transcriptional initiation site. For screening
the variations within the C1GALT1C1 gene, 46 individuals,
including 27 patients with IgAN (six female patients) and 19
normal controls (six female controls), were enrolled. The exon of
C1GALT1C1 gene was amplified from total 58 chromosomes in 46
individuals. PCR primers were designed by Primer3 program.26
Target sequences were amplified by PCR from 50 ng genomic DNA
in 20 ml of final reaction volume. Products were sequenced, on an
ABI PRISM 3700 automated sequencer and analyzed by the Phred/
Phrap/Consed software suite.27,28 Polymorphism loci were detected
using Polyphred29 and were manually confirmed.
Genotyping
Common SNPs (an SNP with a minor allele frequency410%) were
selected as htSNP by the htSNPer1.0. software application according
to the haplotype diversity.30,31 Within a block, this definition
requires that htSNPs should explain the diversity no less than a
threshold of 0.8.31,32 In the C1AGLT1 gene, five tagging SNPs,
designated SNP1 (734C/T), SNP4 (465A/G), SNP6 (330G/T),
SNP7 (292C/), and SNP8 (1365G/A) were fallen into for further
analysis. The SNP8 was genotyped by directed sequencing, and the
other four SNPs were genotyped by the standard PCR-restriction
fragment length polymorphism procedures in all 1164 subjects. The
primers and the restricted endonucleases were listed in Table 5.
Forty PCR products for each SNP locus were resequenced for
accuracy confirmation of PCR-restriction fragment length poly-
morphism analysis.
Statistical analysis
The Fisher exact test was used to determine whether the distribution
of genotypes was consistent with Hardy–Weinberg equilibrium.
Pairwise linkage disequilibrium between each SNP was quantified as
D0 and D2, which were measured by the GLOD software package.33
Haplo.Stats1.2.0 software34 was used to test the association of
statistically inferred haplotypes with IgAN. The levels of the P-value
were adjusted by Bonferroni correction. Because the haplotypes in
this study were constructed by estimation, the omnibus P-value was
assessed empirically by permutation testing with the software.35,36
Descriptive statistical analyses were performed with SPSS10.0
software (SPSS Inc., Chicago, IL USA). A P-value of less than 0.05
was considered statistically significant.
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